{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T02:57:36Z","timestamp":1793069856749,"version":"4.5.0"},"reference-count":76,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,30]],"date-time":"2021-07-30T00:00:00Z","timestamp":1627603200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016838","name":"Berlin Mathematical School","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016838","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005612","name":"Shionogi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005612","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007054","name":"Meso Scale Diagnostics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013226","name":"Les Laboratories Pierre Fabre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008792","name":"Novartis Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.esmoop.2021.100248","type":"journal-article","created":{"date-parts":[[2021,8,23]],"date-time":"2021-08-23T13:02:10Z","timestamp":1629723730000},"page":"100248","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"title":["Fertility preservation and management of pregnancy in melanoma patients requiring systemic therapy"],"prefix":"10.1016","volume":"6","author":[{"given":"J.C.","family":"Hassel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Livingstone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.P.","family":"Allam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.M.","family":"Behre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Bojunga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.H.","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Landsberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Nawroth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Sch\u00fcring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Susok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.M.","family":"Thoms","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Kiesel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Berking","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.esmoop.2021.100248_bib1","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1001\/jamaoncol.2019.2996","article-title":"Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2017: a systematic analysis for the Global Burden of Disease Study","volume":"5","author":"Abate","year":"2019","journal-title":"JAMA Oncol"},{"issue":"10151","key":"10.1016\/j.esmoop.2021.100248_bib2","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0140-6736(18)31559-9","article-title":"Melanoma","volume":"392","author":"Schadendorf","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.esmoop.2021.100248_bib3","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.ejca.2020.02.021","article-title":"Survival of patients with advanced metastatic melanoma: the impact of MAP kinase pathway inhibition and immune checkpoint inhibition\u2014Update 2019","volume":"130","author":"Ugurel","year":"2020","journal-title":"Eur J Cancer"},{"issue":"19","key":"10.1016\/j.esmoop.2021.100248_bib4","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","article-title":"Adjuvant pembrolizumab versus placebo in resected stage III melanoma","volume":"378","author":"Eggermont","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"19","key":"10.1016\/j.esmoop.2021.100248_bib5","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma","volume":"377","author":"Weber","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"19","key":"10.1016\/j.esmoop.2021.100248_bib6","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1056\/NEJMoa1611299","article-title":"Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy","volume":"375","author":"Eggermont","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"19","key":"10.1016\/j.esmoop.2021.100248_bib7","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa1708539","article-title":"Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma","volume":"377","author":"Long","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.esmoop.2021.100248_bib9","doi-asserted-by":"crossref","first-page":"e2027738","DOI":"10.1001\/jamanetworkopen.2020.27738","article-title":"Trends in cancer incidence in US adolescents and young adults, 1973-2015","volume":"3","author":"Scott","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"11","key":"10.1016\/j.esmoop.2021.100248_bib10","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.3390\/cancers12113421","article-title":"Incidence, survival, and mortality trends of cancers diagnosed in adolescents and young adults (15-39 years): a population-based study in the Netherlands 1990-2016","volume":"12","author":"van der Meer","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"4","key":"10.1016\/j.esmoop.2021.100248_bib11","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.jaad.2015.11.014","article-title":"Risk factors and outcomes of cutaneous melanoma in women less than 50 years of age","volume":"74","author":"Tellez","year":"2016","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.esmoop.2021.100248_bib12","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ijwd.2016.12.004","article-title":"Prognosis for women diagnosed with melanoma during, before, or after pregnancy: weighing the evidence","volume":"3","author":"Todd","year":"2017","journal-title":"Int J Womens Dermatol"},{"issue":"7650","key":"10.1016\/j.esmoop.2021.100248_bib13","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"Br Med J"},{"issue":"4","key":"10.1016\/j.esmoop.2021.100248_bib14","first-page":"277","article-title":"New systemic agents in dermatology with respect to fertility, pregnancy, and lactation","volume":"13","author":"Grunewald","year":"2015","journal-title":"J\u00a0Dtsch Dermatol Ges"},{"issue":"1","key":"10.1016\/j.esmoop.2021.100248_bib15","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s00404-017-4594-3","article-title":"Practical recommendations for fertility preservation in women by the FertiPROTEKT network. Part I: indications for fertility preservation","volume":"297","author":"Sch\u00fcring","year":"2018","journal-title":"Arch Gynecol Obstet"},{"issue":"12","key":"10.1016\/j.esmoop.2021.100248_bib16","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1016\/j.annonc.2020.09.006","article-title":"Fertility preservation and post-treatment pregnancies in post-pubertal cancer patients: ESMO Clinical Practice Guidelines","volume":"31","author":"Lambertini","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2021.100248_bib17","doi-asserted-by":"crossref","DOI":"10.1177\/1179558119845865","article-title":"FertiPROTEKT, Oncofertility Consortium and the Danish Fertility-Preservation Networks\u2014what can we learn from their experiences?","volume":"13","author":"von Wolff","year":"2019","journal-title":"Clin Med Insights Reprod Health"},{"key":"10.1016\/j.esmoop.2021.100248_bib18","series-title":"Fertility Preservation in Oncological and Non-Oncological Diseases: A Practical Guide","year":"2020"},{"issue":"11","key":"10.1016\/j.esmoop.2021.100248_bib19","doi-asserted-by":"crossref","first-page":"2683","DOI":"10.1093\/humrep\/dep343","article-title":"The International Committee for Monitoring Assisted Reproductive Technology (ICMART) and the World Health Organization (WHO) revised glossary on ART terminology, 2009","volume":"24","author":"Zegers-Hochschild","year":"2009","journal-title":"Hum Reprod"},{"issue":"6","key":"10.1016\/j.esmoop.2021.100248_bib20","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.rbmo.2012.09.001","article-title":"Ovarian reserve parameters: a comparison between users and non-users of hormonal contraception","volume":"25","author":"Bentzen","year":"2012","journal-title":"Reprod Biomed Online"},{"issue":"1","key":"10.1016\/j.esmoop.2021.100248_bib21","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.rbmo.2019.10.004","article-title":"Ovarian reserve markers after discontinuing long-term use of combined oral contraceptives","volume":"40","author":"Landersoe","year":"2020","journal-title":"Reprod Biomed Online"},{"issue":"6","key":"10.1016\/j.esmoop.2021.100248_bib22","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1093\/humrep\/deab056","article-title":"Antral follicle count and anti-M\u00fcllerian hormone to classify low-prognosis women under the POSEIDON criteria: a classification agreement study of over 9000 patients","volume":"36","author":"Esteves","year":"2021","journal-title":"Hum Reprod"},{"issue":"4","key":"10.1016\/j.esmoop.2021.100248_bib23","doi-asserted-by":"crossref","first-page":"hoaa052","DOI":"10.1093\/hropen\/hoaa052","article-title":"ESHRE guideline: female fertility preservation","volume":"2020","author":"Anderson","year":"2020","journal-title":"Hum Reprod Open"},{"issue":"6","key":"10.1016\/j.esmoop.2021.100248_bib24","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1093\/humrep\/den108","article-title":"Relevance of anti-Mullerian hormone measurement in a routine IVF program","volume":"23","author":"Gnoth","year":"2008","journal-title":"Hum Reprod"},{"issue":"6","key":"10.1016\/j.esmoop.2021.100248_bib25","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.1210\/jc.2003-030824","article-title":"Menopause transition: annual changes in serum hormonal patterns over the menstrual cycle in women during a nine-year period prior to menopause","volume":"89","author":"Landgren","year":"2004","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.esmoop.2021.100248_bib26","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1093\/humupd\/dmp048","article-title":"World Health Organization reference values for human semen characteristics","volume":"16","author":"Cooper","year":"2010","journal-title":"Hum Reprod Update"},{"issue":"1","key":"10.1016\/j.esmoop.2021.100248_bib28","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.yrtph.2015.07.022","article-title":"Impact analysis of ICH S9 on non-clinical development of anticancer drugs","volume":"73","author":"Bonelli","year":"2015","journal-title":"Regul Toxicol Pharmacol"},{"issue":"44","key":"10.1016\/j.esmoop.2021.100248_bib29","first-page":"10487","article-title":"International Conference on Harmonisation; Guidance on S9 Nonclincal Evaluation for Anticancer Pharmaceuticals; availability. Notice","volume":"75","year":"2010","journal-title":"Fed Regist"},{"issue":"2","key":"10.1016\/j.esmoop.2021.100248_bib30","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1002\/bdrb.21176","article-title":"An evaluation of the impact of PD-1 pathway blockade on reproductive safety of therapeutic PD-1 inhibitors","volume":"107","author":"Poulet","year":"2016","journal-title":"Birth Defects Res B Dev Reprod Toxicol"},{"issue":"7","key":"10.1016\/j.esmoop.2021.100248_bib40","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1056\/NEJMoa1904059","article-title":"Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma","volume":"381","author":"Robert","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.esmoop.2021.100248_bib41","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/S1470-2045(16)30122-X","article-title":"Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial","volume":"17","author":"Ascierto","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2021.100248_bib42","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ejca.2019.11.016","article-title":"Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma","volume":"126","author":"Ascierto","year":"2020","journal-title":"Eur J Cancer"},{"issue":"9948","key":"10.1016\/j.esmoop.2021.100248_bib43","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/S0140-6736(14)60958-2","article-title":"Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial","volume":"384","author":"Robert","year":"2014","journal-title":"Lancet"},{"issue":"16","key":"10.1016\/j.esmoop.2021.100248_bib44","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-year survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.esmoop.2021.100248_bib45","doi-asserted-by":"crossref","first-page":"e000491","DOI":"10.1136\/esmoopen-2019-000491","article-title":"Tolerability of BRAF\/MEK inhibitor combinations: adverse event evaluation and management","volume":"4","author":"Heinzerling","year":"2019","journal-title":"ESMO Open"},{"key":"10.1016\/j.esmoop.2021.100248_bib46","doi-asserted-by":"crossref","first-page":"232","DOI":"10.3389\/fonc.2020.00232","article-title":"Fertility outcomes and sperm-DNA parameters in metastatic melanoma survivors receiving vemurafenib or dabrafenib therapy: case report","volume":"10","author":"Ghezzi","year":"2020","journal-title":"Front Oncol"},{"issue":"8","key":"10.1016\/j.esmoop.2021.100248_bib47","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1080\/0284186X.2018.1449251","article-title":"Fatherhood during dabrafenib and trametinib therapy for metastatic melanoma","volume":"57","author":"Cocorocchio","year":"2018","journal-title":"Acta Oncol"},{"issue":"8","key":"10.1016\/j.esmoop.2021.100248_bib48","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1001\/jamaoncol.2020.1641","article-title":"Association of impaired spermatogenesis with the use of immune checkpoint inhibitors in patients with metastatic melanoma","volume":"6","author":"Scovell","year":"2020","journal-title":"JAMA Oncol"},{"issue":"7","key":"10.1016\/j.esmoop.2021.100248_bib49","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1634\/theoncologist.2018-0722","article-title":"Severe epididymo-orchitis and encephalitis complicating anti-PD-1 therapy","volume":"24","author":"Quach","year":"2019","journal-title":"Oncologist"},{"issue":"4","key":"10.1016\/j.esmoop.2021.100248_bib50","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1093\/annonc\/mdw696","article-title":"Immune checkpoint inhibitors-related orchitis","volume":"28","author":"Brunet-Possenti","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2021.100248_bib51","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ejca.2021.04.031","article-title":"Male fertility during and after immune checkpoint inhibitor therapy: a cross-sectional pilot study","volume":"152","author":"Salzmann","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.esmoop.2021.100248_bib52","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ctrv.2016.02.003","article-title":"Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy","volume":"45","author":"Eigentler","year":"2016","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.esmoop.2021.100248_bib53","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ctrv.2017.05.003","article-title":"Combined immune checkpoint blockade (anti-PD-1\/anti-CTLA-4): evaluation and management of adverse drug reactions","volume":"57","author":"Hassel","year":"2017","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"10.1016\/j.esmoop.2021.100248_bib54","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.rbmo.2020.02.008","article-title":"Fertility in female cancer survivors: a systematic review and meta-analysis","volume":"41","author":"Busnelli","year":"2020","journal-title":"Reprod Biomed Online"},{"issue":"5","key":"10.1016\/j.esmoop.2021.100248_bib55","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1210\/er.2017-00232","article-title":"The RASopathy family: consequences of germline activation of the RAS\/MAPK pathway","volume":"39","author":"Tajan","year":"2018","journal-title":"Endocr Rev"},{"issue":"11","key":"10.1016\/j.esmoop.2021.100248_bib56","doi-asserted-by":"crossref","first-page":"e192","DOI":"10.1200\/JCO.2012.45.2870","article-title":"Treatment of metastatic malignant melanoma with vemurafenib during pregnancy","volume":"31","author":"Maleka","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2021.100248_bib57","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1097\/CMR.0000000000000600","article-title":"Partial response of metastatic melanoma to BRAF-inhibitor-monotherapy in a pregnant patient with no fetal toxicity","volume":"29","author":"Marc\u00e9","year":"2019","journal-title":"Melanoma Res"},{"issue":"1","key":"10.1016\/j.esmoop.2021.100248_bib58","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1159\/000487128","article-title":"Severe adverse reaction to vemurafenib in a pregnant woman with metastatic melanoma","volume":"11","author":"de Haan","year":"2018","journal-title":"Case Rep Oncol"},{"key":"10.1016\/j.esmoop.2021.100248_bib59","doi-asserted-by":"crossref","first-page":"e00142","DOI":"10.1016\/j.crwh.2019.e00142","article-title":"Treatment of metastatic malignant melanoma during pregnancy with a BRAF kinase inhibitor","volume":"24","author":"Pagan","year":"2019","journal-title":"Case Rep Womens Health"},{"issue":"3","key":"10.1016\/j.esmoop.2021.100248_bib60","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1053\/j.seminoncol.2018.03.005","article-title":"A\u00a0comparative analysis of immune privilege in pregnancy and cancer in the context of checkpoint blockade immunotherapy","volume":"45","author":"Flint","year":"2018","journal-title":"Semin Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2021.100248_bib61","doi-asserted-by":"crossref","first-page":"e20182232","DOI":"10.1084\/jem.20182232","article-title":"PD-1 restraint of regulatory T cell suppressive activity is critical for immune tolerance","volume":"218","author":"Tan","year":"2021","journal-title":"J\u00a0Exp Med"},{"issue":"3","key":"10.1016\/j.esmoop.2021.100248_bib62","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1053\/j.seminoncol.2018.03.003","article-title":"Viable pregnancy in a patient with metastatic melanoma treated with double checkpoint immunotherapy","volume":"45","author":"Burotto","year":"2018","journal-title":"Semin Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2021.100248_bib63","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1093\/molehr\/5.1.84","article-title":"The CTLA-4 gene is expressed in placental fibroblasts","volume":"5","author":"Kaufman","year":"1999","journal-title":"Mol Hum Reprod"},{"issue":"2","key":"10.1016\/j.esmoop.2021.100248_bib64","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1084\/jem.20050019","article-title":"A\u00a0critical role for the programmed death ligand 1 in fetomaternal tolerance","volume":"202","author":"Guleria","year":"2005","journal-title":"J\u00a0Exp Med"},{"issue":"8","key":"10.1016\/j.esmoop.2021.100248_bib65","doi-asserted-by":"crossref","first-page":"5211","DOI":"10.4049\/jimmunol.179.8.5211","article-title":"A\u00a0link between PDL1 and T regulatory cells in fetomaternal tolerance","volume":"179","author":"Habicht","year":"2007","journal-title":"J\u00a0Immunol"},{"issue":"5","key":"10.1016\/j.esmoop.2021.100248_bib66","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/j.1600-0897.2009.00737.x","article-title":"PD-1 but not CTLA-4 blockage abrogates the protective effect of regulatory T cells in a pregnancy murine model","volume":"62","author":"Wafula","year":"2009","journal-title":"Am J Reprod Immunol"},{"issue":"9","key":"10.1016\/j.esmoop.2021.100248_bib67","doi-asserted-by":"crossref","first-page":"4530","DOI":"10.4049\/jimmunol.1002031","article-title":"The link between the PDL1 costimulatory pathway and Th17 in fetomaternal tolerance","volume":"187","author":"D'Addio","year":"2011","journal-title":"J\u00a0Immunol"},{"issue":"2","key":"10.1016\/j.esmoop.2021.100248_bib68","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ctrv.2009.11.007","article-title":"Treatment of the pregnant mother with cancer: a systematic review on the use of cytotoxic, endocrine, targeted agents and immunotherapy during pregnancy. Part I: solid tumors","volume":"36","author":"Azim","year":"2010","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.esmoop.2021.100248_bib69","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.ejca.2018.09.008","article-title":"Immunotherapy with ipilimumab plus nivolumab in a stage IV melanoma patient during pregnancy","volume":"104","author":"Menzer","year":"2018","journal-title":"Eur J Cancer"},{"issue":"4","key":"10.1016\/j.esmoop.2021.100248_bib70","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.fertnstert.2020.08.011","article-title":"Utility of gonadotropin-releasing hormone agonists for fertility preservation in women receiving chemotherapy: pros and cons","volume":"114","author":"Dolmans","year":"2020","journal-title":"Fertil Steril"},{"issue":"6","key":"10.1016\/j.esmoop.2021.100248_bib71","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.fertnstert.2019.09.013","article-title":"Fertility preservation in patients undergoing gonadotoxic therapy or gonadectomy: a committee opinion","volume":"112","year":"2019","journal-title":"Fertil Steril"},{"issue":"5","key":"10.1016\/j.esmoop.2021.100248_bib72","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.fertnstert.2021.03.008","article-title":"Transplantation of cryopreserved ovarian tissue in a series of 285 women: a review of five leading European centers","volume":"115","author":"Dolmans","year":"2021","journal-title":"Fertil Steril"},{"issue":"11","key":"10.1016\/j.esmoop.2021.100248_bib73","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1093\/annonc\/mdz284","article-title":"Preserving fertility in female patients with hematological malignancies: a multidisciplinary oncofertility approach","volume":"30","author":"Salama","year":"2019","journal-title":"Ann Oncol"},{"issue":"19","key":"10.1016\/j.esmoop.2021.100248_bib74","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1200\/JCO.2018.78.1914","article-title":"Fertility preservation in patients with cancer: ASCO clinical practice guideline update","volume":"36","author":"Oktay","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2021.100248_bib75","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.critrevonc.2019.03.010","article-title":"EUropean REcommendations for female FERtility preservation (EU-REFER): a joint collaboration between oncologists and fertility specialists","volume":"138","author":"Dolmans","year":"2019","journal-title":"Crit Rev Oncol Hematol"},{"issue":"suppl 6","key":"10.1016\/j.esmoop.2021.100248_bib76","doi-asserted-by":"crossref","first-page":"vi160","DOI":"10.1093\/annonc\/mdt199","article-title":"Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"24","author":"Peccatori","year":"2013","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2021.100248_bib77","doi-asserted-by":"crossref","first-page":"66","DOI":"10.6004\/jnccn.2018.0001","article-title":"Adolescent and young adult oncology, version 2.2018, NCCN clinical practice guidelines in oncology","volume":"16","author":"Coccia","year":"2018","journal-title":"J\u00a0Natl Compr Canc Netw"},{"issue":"1","key":"10.1016\/j.esmoop.2021.100248_bib78","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s00404-017-4595-2","article-title":"Practical recommendations for fertility preservation in women by the FertiPROTEKT network. Part II: fertility preservation techniques","volume":"297","author":"von Wolff","year":"2018","journal-title":"Arch Gynecol Obstet"},{"issue":"11","key":"10.1016\/j.esmoop.2021.100248_bib79","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.3390\/cells8111463","article-title":"Estrogen receptors and melanoma: a review","volume":"8","author":"Dika","year":"2019","journal-title":"Cells"},{"issue":"2","key":"10.1016\/j.esmoop.2021.100248_bib80","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.ijwd.2017.11.006","article-title":"Pregnancy and melanoma: recommendations for clinical scenarios","volume":"4","author":"Berk-Krauss","year":"2018","journal-title":"Int J Womens Dermatol"},{"issue":"6","key":"10.1016\/j.esmoop.2021.100248_bib81","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1055\/a-0611-5549","article-title":"Fertility preservation for patients with malignant disease. Guideline of the DGGG, DGU and DGRM (S2k-Level, AWMF Registry No.\u2009015\/082, November 2017)\u2014recommendations and statements for girls and women","volume":"78","author":"Dittrich","year":"2018","journal-title":"Geburtshilfe Frauenheilkd"},{"key":"10.1016\/j.esmoop.2021.100248_bib82","doi-asserted-by":"crossref","first-page":"103092","DOI":"10.1016\/j.critrevonc.2020.103092","article-title":"Fertility preservation in women with cervical cancer","volume":"154","author":"Somigliana","year":"2020","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.esmoop.2021.100248_bib83","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ctrv.2017.07.001","article-title":"Fertility and pregnancy issues in BRCA-mutated breast cancer patients","volume":"59","author":"Lambertini","year":"2017","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.esmoop.2021.100248_bib84","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ctrv.2016.06.010","article-title":"Fertility preservation in women with borderline ovarian tumours","volume":"49","author":"Mangili","year":"2016","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.esmoop.2021.100248_bib85","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ctrv.2018.11.006","article-title":"Ovarian protection with gonadotropin-releasing hormone agonists during chemotherapy in cancer patients: from biological evidence to clinical application","volume":"72","author":"Lambertini","year":"2019","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.esmoop.2021.100248_bib86","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ctrv.2016.11.006","article-title":"Chemotherapy-related late adverse effects on ovarian function in female survivors of childhood and young adult cancer: a systematic review","volume":"53","author":"Overbeek","year":"2017","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.esmoop.2021.100248_bib87","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.ctrv.2017.04.009","article-title":"State of the art on oocyte cryopreservation in female cancer patients: a critical review of the literature","volume":"57","author":"Massarotti","year":"2017","journal-title":"Cancer Treat Rev"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S205970292100209X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S205970292100209X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T20:28:39Z","timestamp":1761856119000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S205970292100209X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":76,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["S205970292100209X"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2021.100248","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fertility preservation and management of pregnancy in melanoma patients requiring systemic therapy","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2021.100248","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100248"}}